Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions

详细信息    查看全文

• 作者：Hongqin Zhuang (1)
  Weiwei Jiang (1)
  Xiangyu Zhang (1)
  Fan Qiu (1)
  Ziyi Gan (1)
  Wei Cheng (1)
  Jing Zhang (1)
  Shengwen Guan (4)
  Bo Tang (4)
  Qilai Huang (1) (2)
  Xinhua Wu (3)
  Xiaofeng Huang (1)
  Wenhui Jiang (1)
  Qingang Hu (1)
  Min Lu (1)
  Zi-Chun Hua (1) (2) (4)
  
• 关键词：HSP70 ; HSP27 ; TRAIL ; Tumor therapy ; Drug sensitivity
• 刊名：Journal of Molecular Medicine
• 出版年：2013
• 出版时间：February 2013
• 年：2013
• 卷：91
• 期：2
• 页码：219-235
• 全文大小：1480KB
• 参考文献：1. McCracken M, Olsen M, Chen MS Jr, Jemal A, Thun M, Cokkinides V, Deapen D, Ward E (2007) Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 57:190-05 CrossRef
  2. Erridge SC, Moller H, Price A, Brewster D (2007) International comparisons of survival from lung cancer: pitfalls and warnings. Nat Clin Pract Oncol 4:570-77 CrossRef
  3. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-63 CrossRef
  4. Baetu TM, Hiscott J (2002) On the TRAIL to apoptosis. Cytokine Growth Factor Rev 13:199-07 CrossRef
  5. Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33-2 CrossRef
  6. Hietakangas V, Poukkula M, Heiskanen KM, Karvinen JT, Sistonen L, Eriksson JE (2003) Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol Cell Biol 23:1278-291 CrossRef
  7. Jaattela M (1999) Escaping cell death: survival proteins in cancer. Exp Cell Res 248:30-3 CrossRef
  8. Jolly C, Morimoto RI (2000) Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 92:1564-572 CrossRef
  9. Hannon GJ (2002) RNA interference. Nature 418:244-51 CrossRef
  10. Rocchi P, Jugpal P, So A, Sinneman S, Ettinger S, Fazli L, Nelson C, Gleave M (2006) Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU Int 98:1082-089 CrossRef
  11. Chatterjee M, Jain S, Stuhmer T, Andrulis M, Ungethum U, Kuban RJ, Lorentz H, Bommert K, Topp M, Kramer D et al (2007) STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 109:720-28 CrossRef
  12. Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, Kumaraswamy S, Balasis M, Greedy B, Armitage ES et al (2005) Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 65:10536-0544 CrossRef
  13. Zhuang H, Jiang W, Cheng W, Qian K, Dong W, Cao L, Huang Q, Li S, Dou F, Chiu JF et al (2010) Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis. Lung Cancer 68:27-8 CrossRef
  14. Schreiber E, Matthias P, Muller MM, Schaffner W (1989) Rapid detection of octamer binding proteins with ‘mini-extracts- prepared from a small number of cells. Nucleic Acids Res 17:6419 CrossRef
  15. Cao L, Du P, Jiang SH, Jin GH, Huang QL, Hua ZC (2008) Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Mol Cancer Ther 7:851-61 CrossRef
  16. bou El Hassan MA, Verheul HM, Jorna AS, Schalkwijk C, van Bezu J, van der Vijgh WJ, Bast A (2003) The new cardioprotector monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro. Br J Cancer 89:357-62
  17. McLemore TL, Eggleston JC, Shoemaker RH, Abbott BJ, Bohlman ME, Liu MC, Fine DL, Mayo JG, Boyd MR (1988) Comparison of intrapulmonary, percutaneous intrathoracic, and subcutaneous models for the propagation of human pulmonary and nonpulmonary cancer cell lines in athymic nude mice. Cancer Res 48:2880-886
  18. LeBlanc HN, Ashkenazi A (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10:66-5 CrossRef
  19. Shi Y, Tu Z, Tang D, Zhang H, Liu M, Wang K, Calderwood SK, Xiao X (2006) The inhibition of LPS-induced production of inflammatory cytokines by HSP70 involves inactivation of the NF-kappaB pathway but not the MAPK pathways. Shock 26:277-84 CrossRef
  20. Mendoza FJ, Ishdorj G, Hu X, Gibson SB (2008) Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment. Apoptosis 13:756-70 CrossRef
  21. Panner A, Crane CA, Weng C, Feletti A, Fang S, Parsa AT, Pieper RO (2010) Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res 70:5046-053 CrossRef
  22. Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH (2009) Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Biochem Pharmacol 77:1328-336 CrossRef
  23. Kaunisto A, Kochin V, Asaoka T, Mikhailov A, Poukkula M, Meinander A, Eriksson JE (2009) PKC-mediated phosphorylation regulates c-FLIP ubiquitylation and stability. Cell Death Differ 16:1215-226 CrossRef
  24. Tomasetti M, Andera L, Alleva R, Borghi B, Neuzil J, Procopio A (2006) Alpha-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: implication for sensitisation of resistant cancer cells to TRAIL apoptosis. FEBS Lett 580:1925-931 CrossRef
  25. Bode AM, Dong Z (2004) Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4:793-05 CrossRef
  26. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G (2006) Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5:2592-601 CrossRef
  27. Ma Y, Lakshmikanthan V, Lewis RW, Kumar MV (2006) Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. Mol Cancer Ther 5:170-78 CrossRef
  28. Dutton A, Young LS, Murray PG (2006) The role of cellular FLICE inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer. Expert Opin Ther Targets 10:27-5 CrossRef
  29. Lee JS, Lee JJ, Seo JS (2005) HSP70 deficiency results in activation of c-Jun N-terminal kinase, extracellular signal-regulated kinase, and caspase-3 in hyperosmolarity-induced apoptosis. J Biol Chem 280:6634-641 CrossRef
  30. Gao T, Newton AC (2002) The turn motif is a phosphorylation switch that regulates the binding of Hsp70 to protein kinase C. J Biol Chem 277:31585-1592 CrossRef
  31. Kucharczak J, Simmons MJ, Fan Y, Gelinas C (2003) To be, or not to be: NF-kappaB is the answer—role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 22:8961-982 CrossRef
  32. Dutta J, Fan Y, Gupta N, Fan G, Gelinas C (2006) Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 25:6800-816 CrossRef
  33. Shetty S, Graham BA, Brown JG, Hu X, Vegh-Yarema N, Harding G, Paul JT, Gibson SB (2005) Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 25:5404-416 CrossRef
  34. Ouyang DY, Wang YY, Zheng YT (2005) Activation of c-Jun N-terminal kinases by ribotoxic stresses. Cell Mol Immunol 2:419-25
  35. Dhanasekaran DN, Reddy EP (2008) JNK signaling in apoptosis. Oncogene 27:6245-251 CrossRef
  36. Liu X, Yue P, Khuri FR, Sun SY (2004) p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 64:5078-083 CrossRef
  37. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace AJ Jr, El-Deiry WS (1998) p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 58:1593-598
  38. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, Karin M (2006) The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 124:601-13 CrossRef
  
• 作者单位：Hongqin Zhuang (1)
  Weiwei Jiang (1)
  Xiangyu Zhang (1)
  Fan Qiu (1)
  Ziyi Gan (1)
  Wei Cheng (1)
  Jing Zhang (1)
  Shengwen Guan (4)
  Bo Tang (4)
  Qilai Huang (1) (2)
  Xinhua Wu (3)
  Xiaofeng Huang (1)
  Wenhui Jiang (1)
  Qingang Hu (1)
  Min Lu (1)
  Zi-Chun Hua (1) (2) (4)
  
  1. The State Key Laboratory of Pharmaceutical Biotechnology, College of Life Science and School of Stomatology, Affiliated Stomatological Hospital, Nanjing University, 22 Han Kou Road, Nanjing, 210093, Jiangsu, People’s Republic of China
  4. Changzhou High-Tech Research Institute of Nanjing University and Jiangsu TargetPharma Laboratories Inc., Changzhou, 213164, Jiangsu, People’s Republic of China
  2. The State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine, Macau University of Science and Technology, Macau, China
  3. Affiliated Hospital of Nantong Medical College, Nantong, 226001, Jiangsu, People’s Republic of China
  
• ISSN：1432-1440

文摘

Many cancer cell types are resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Here, we examined whether HSP70 suppression by small interfering RNA (siRNA) sensitized non-small cell lung cancer (NSCLC) cells to TRAIL-induced apoptosis and the underlying mechanisms. We demonstrated that HSP70 suppression by siRNA sensitized NSCLC cells to TRAIL-induced apoptosis by upregulating the expressions of death receptor 4 (DR4) and death receptor 5 (DR5) through activating NF-κB, JNK, and, subsequently, p53, consequently significantly amplifying TRAIL-mediated caspase-8 processing and activity, cytosolic translocation of cytochrome c, and cell death. Consistently, the pro-apoptotic proteins Bad and Bax were upregulated, while the anti-apoptotic protein Bcl-2 was downregulated. The luciferase activity of the DR4 promoter was blocked by a NF-κB pathway inhibitor BAY11-7082, suggesting that NF-κB activation plays an important role in the transcriptional upregulation of DR4. Additionally, HSP70 suppression inhibited the phosphorylation of ERK, AKT, and PKC, thereby downregulating c-FLIP-L. A549 xenografts in mice receiving HSP70 siRNA showed TRAIL-induced cell death and increased DR4/DR5 levels and reduced tumor growth. The combination of psiHSP70 gene therapy with TRAIL also significantly increased the survival benefits induced by TRAIL therapy alone. Interestingly, HSP27 siRNA and TRAIL together could not suppress tumor growth or prolong the survival of tumor-bearing mice significantly, although the combination could efficiently induce the apoptosis of A549 cells in vitro. Our findings suggest that HSP70 suppression or downregulation might be promising to overcome TRAIL resistance in cancer.